DLA Piper Canada represented the underwriters in $149.5 million offering of Columbia Care ‎shares

On January 13, 2021, Columbia Care Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care”) announced the closing of a bought deal public ‎offering of common shares for ‎gross proceeds of $149.5 million.‎‎ ‎DLA Piper Canada acted as Canadian counsel to the underwriters in connection ‎with the offering.

Canaccord Genuity Corp. acted as sole book-runner and co-lead ‎underwriter, along with ATB Capital Markets Inc., on behalf of a syndicate of underwriters including Beacon Securities Limited, Eight Capital, Echelon Wealth Partners Inc., ‎Paradigm Capital Inc. and PI Financial Corp.

The offering was conducted in each of the provinces of Canada, other than Québec, pursuant to a prospectus supplement to the Company’s base shelf prospectus dated September 2, 2020 and elsewhere outside of Canada on a private placement basis.

One of the largest and most experienced cultivators, manufacturers and providers of medical and adult use cannabis products and related services, Columbia Care has licenses in 18 US jurisdictions and the EU and operates 108 facilities, including 81 dispensaries and 27 cultivation and manufacturing facilities. It is one of the original providers of medical cannabis in the United States.

The DLA Piper Canada deal team on this transaction was led by Derek Sigel and Robert Fonn and included Sydney Kert, Jamie Mandell, Grace Latimer, Kevin Fritz (tax) and articling student, Stephen Viscomi‎.